Chemotherapy-induced peripheral neurotoxicity (CIPN): an update

AA Argyriou, J Bruna, P Marmiroli, G Cavaletti - Critical reviews in oncology …, 2012 - Elsevier
The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …

Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

AA Argyriou, AP Kyritsis, T Makatsoris… - Cancer management …, 2014 - Taylor & Francis
Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic
peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome …

Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update

GA Masters, S Temin, CG Azzoli, G Giaccone… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Update on taxane development: new analogs and new formulations

JA Yared, KHR Tkaczuk - Drug design, development and therapy, 2012 - Taylor & Francis
The taxanes (paclitaxel and docetaxel) represent an important class of antineoplastic agents
that interfere with microtubule function leading to altered mitosis and cellular death …

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

H Kenmotsu, Y Tanigawara - Cancer science, 2015 - Wiley Online Library
Docetaxel (Taxotere®) has been one of the most important chemotherapeutic drugs for
cancer treatment since 1996. Although a large number of clinical studies have been …

[HTML][HTML] Q-learning with censored data

Y Goldberg, MR Kosorok - Annals of statistics, 2012 - ncbi.nlm.nih.gov
We develop methodology for a multistage-decision problem with flexible number of stages in
which the rewards are survival times that are subject to censoring. We present a novel Q …

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line

NB Leighl - Current oncology, 2012 - mdpi.com
Metastatic non-small-cell lung cancer (NSCLC) is the leading cause of cancer mortality in
Canada. Although treatment outcomes in advanced disease remain modest, with paradigm …

Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis

JFP Bridges, AF Mohamed, HW Finnern, A Woehl… - Lung Cancer, 2012 - Elsevier
BACKGROUND: Treatment decisions for advanced non-small cell lung cancer (NSCLC) are
complex and require trade-offs between the benefits and risks experienced by patients. We …

Modifications on the basic skeletons of vinblastine and vincristine

P Keglevich, L Hazai, G Kalaus, C Szántay - Molecules, 2012 - mdpi.com
The synthetic investigation of biologically active natural compounds serves two main
purposes:(i) the total synthesis of alkaloids and their analogues;(ii) modification of the …

New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer

Y Zhang, SH Yang, XL Guo - Biomedicine & pharmacotherapy, 2017 - Elsevier
Nowadays, lung cancer, as a health problem in worldwide, has high mortality both in men
and women. Despite advances in diagnosis and surgical techniques of lung cancer in recent …